Higher rates of autism in children with various congenital disorders
Children with Congenital Heart Disease, Tuberous Sclerosis Complex, Duchenne Muscular Dystrophy, Ehlers-Danlos Syndrome suffer high rates of autism.
Congenital heart defects (CHD) and autism
In the first two studies of their kind a positive association was found between congenital heart defects in infants and risk of developing autism symptoms later in life. In the first case, a team of clinicians and researchers from The Children’s Hospital of Philadelphia screened 195 children with a history of congenital heart defects. Measures included behavioural data from neurodevelopmental evaluations from four years previously, and parent-report data from a later annual follow-up.
These findings showed much higher risk of autism in this group compared to the rates of autism in the general population. The study also found that children with a history of severe CHD requiring infant surgery were at the highest risk for screening positive for autism symptoms.
In the second paper, which was based on a nationwide population-based case-control study of a Taiwanese cohort of 3552 children, CHD was once again identified as an independent risk factor for both ADHD and autism. The authors highlight the need for a careful screening and specialist referral to assess the presence of social-communication problems, with the view of offering early intervention in order to achieve best possible outcomes in children with CHD.
Muscular dystrophy and autism
A recent investigation on a cohort of boys with Duchene Muscular Dystrophy has observed significantly higher rate of autism compared to general population, thus confirming earlier findings of increased prevalence of cognitive and neurodevelopmental disorders in patients with muscular dystrophies.
Tuberous sclerosis complex (TSC) and autism
TSC is associated with a high neurological and neuropsychiatric morbidity, including seizures, aggressive behaviours and autism. The mammalian/ mechanistic target of rapamycin (mTOR) pathway is a key signalling pathway that has been implicated in TSC as well as cognitive impairments, neurodegenerative diseases and genetic epilepsy syndromes. Although the precise pathological mechanisms behind the emergence of autism and other neurophsychiatric manifestations in TSC are still unknown, microglial activation as a downstream consequences of the lack of inhibition of the mTOR pathway is suspected to play a major role.
Everolimus, a potent mTOR inhibitor with strong neuro-inflammation attenuating effects, has been observed to lead to a reduction in autism symptoms in some children who suffer concurrent TSC, epilepsy and autism. It is believed that TSC therefore offers a valuable model for understanding and treating the mechanisms that underlie idiopathic autism.
(Ishii et al. 2015)
“Patients in this study showed improvement in the social communication deficits and in restricted and repetitive behaviors. These preliminary data suggest that everolimus can improve symptoms related to ASD in patients with TSC.”
(Mizuguchi et al. 2018)
Neurofibromatosis Type 1 (NF1) and autism
NF1 is another monogenetic disorder with a very high incidence of neuropsychiatric disorders and cognitive impairments, with almost three quarters of affected children suffering speech and language delays, and an estimated quarter meeting full diagnostic criteria for autism.
Ehlers-Danlos Syndrome (EDS) and autism
A recent Swedish nationwide population-based matched cohort study found that individuals with EDS are at increased risks of many psychiatric disorders, including autism. These risk increases may have a genetic and/or early environmental background, as suggested by the evidence showing that siblings of EDS patients also have elevated risks of certain psychiatric disorders.
Edited to add:
Cerebral Palsy and autism
In a recent large Swedish population-based study, the rate of autism amongst children with cerebral palsy was found to be 18%, confirming results of earlier studies that found autism and ADHD to be more common in people with CP than in the general population.
Bean Jaworski J.L., Flynn T., Burnham N., et al. (2017) Rates of autism and potential risk factors in children with congenital heart defects. Congenit Heart Dis. Mar 16. doi: 10.1111/chd.12461.
Cederlöf M, Larsson H, Lichtenstein P, et al. (2016) Nationwide population-based cohort study of psychiatric disorders in individuals with Ehlers-Danlos syndrome or hypermobility syndrome and their siblings. BMC Psychiatry. Jul 4;16:207. doi: 10.1186/s12888-016-0922-6.
Colombo P., Nobile M., Tesei A., et al. (2017) Assessing mental health in boys with Duchenne muscular dystrophy: Emotional, behavioural and neurodevelopmental profile in an Italian clinical sample. Eur J Paediatr Neurol. Mar 24. pii: S1090-3798(17)30183-6. doi: 10.1016/j.ejpn.2017.02.007.
Craig F., Savino R., Trabacca A. (2019) A systematic review of comorbidity between cerebral palsy, autism spectrum disorders and Attention Deficit Hyperactivity
Disorder. Eur J Paediatr Neurol. Jan;23(1):31-42. doi: 10.1016/j.ejpn.2018.10.005.
Kilincaslan, A., Kok, B., Tekturk, P., Yalcinkaya, C., Ozkara, C. and Yapici, Z. (2017). Beneficial Effects of Everolimus on Autism and Attention-Deficit/Hyperactivity Disorder Symptoms in a Group of Patients with Tuberous Sclerosis Complex. Journal of Child and Adolescent Psychopharmacology, 27(4), pp.383-388. doi: 10.1089/cap.2016.0100.
Mitchell R., Barton S., Harvey A.S., et al. (2017) Risk factors for the development of autism spectrum disorder in children with tuberous sclerosis complex: protocol for a systematic review. Syst Rev. Mar 8;6(1):49. doi: 10.1186/s13643-017-0448-0.
Mizuguchi, M., Ikeda, H., Kagitani-Shimono, K., Yoshinaga, H., Suzuki, Y., Aoki, M., Endo, M., Yonemura, M. and Kubota, M. (2018). Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan. Brain and Development. doi: 10.1016/j.braindev.2018.07.003.
Morris S.M., Acosta M.T., Garg S., et al. (2016) Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT). JAMA Psychiatry. Dec1;73(12):1276-1284. doi: 10.1001/jamapsychiatry.2016.2600.
Påhlman M., Gillberg C. and Himmelmann K. (2019) One third of school-aged children with cerebral palsy have neuropsychiatric impairments in a population-based study. Acta Paediatr. May 11. doi: 10.1111/apa.14844.
Tsao P.C., Lee Y.S., Jeng M.J., et al. (2017) Additive effect of congenital heart disease and early developmental disorders on attention-deficit/hyperactivity disorder and autism spectrum disorder: a nationwide population-based longitudinal study. Eur Child Adolesc Psychiatry. Apr 17. doi: 10.1007/s00787-017-0989-8.
Wilbur C., Sanguansermsri C., Chable H., et al. (2107) Manifestations of Tuberous Sclerosis Complex: The Experience of a Provincial Clinic. Can J Neurol Sci. Jan;44(1):35-43. doi: 10.1017/cjn.2016.311.
Sato A. (2016) mTOR, a Potential Target to Treat Autism Spectrum Disorder. CNS Neurol Disord Drug Targets. 15(5):533-43. Doi: 10.2174/1871527315666160413120638.
Yang M.T., Lin Y.C., Ho W.H.,( 2017) Everolimus is better than rapamycin in attenuating neuroinflammation in kainic acid-induced seizures. J Neuroinflammation. Jan 21;14(1):15. doi: 10.1186/s12974-017-0797-6.
Young H.K., Barton B.A., Waisbren S., (2008) Cognitive and psychological profile of males with Becker muscular dystrophy. J Child Neurol. Feb;23(2):155-62. doi: 0.1177/0883073807307975.
High rates of depression and suicide in autism Depression is a common and serious problem in autism, and one of the main contributors to poor quality of life. Both children and adults with autism experience high rates of depression and other mood disorders. One...
Autoimmune encephalitis is a class of inflammatory diseases of the brain that can present with a wide spectrum of neurological and psychiatric symptoms. The word autoimmune means that the body, or the person’s immune system, is attacking its own healthy tissues.What...
‘From Bench to Biopharma’ International Conference on Translational Research in Autism – Day 1 Recap
Synchrony symposia, organised by The BRAIN Foundation in partnership with UC Davis MIND Institute and CalTech, is the first and only international conference on translational research in autism that brings together academia, biotech, pharmaceutical companies and...
The Synapse Centre for NeurodevelopmentThe Synapse Centre, based within the ESNEFT (East Suffolk and North Essex NHS Foundation Trust) is a new research centre based in the East of England looking to translate biomedical research into practical therapies for local...
“We must first recognise ASD as a whole body disorder” Autism, or Autism Spectrum Disorder ASD, is traditionally seen as the result of behavioural and neuropsychiatric dysfunction. However there is a strong evidence that various physical, or biomedical, problems can...
The first Brain Foundation annual symposia, Pleasanton, California 8-10 of Nov 2019, aimed to connect researchers with clinicians, donors & stake holders to help translate research efforts into evidence-based treatments for autism and its co-morbidities. It highlighted the need for multidisciplinary collaboration, detailed diagnostics and personalised treatment…
One of the treatment modalities that has shown the greatest promise for reducing symptoms of autism in recent years is transcranial direct current stimulation (tDCS). The most recent study confirmed and expanded on the findings of previous investigations, which strongly indicate that tDCS could have positive effects on cognition, behaviour and physical health, and improve quality of life and autonomy for a large percentage of individuals with autism.
Several studies published in recent months investigated the effects of cannabis-based products for treating autism. Although the studies were open-label and relatively small in scale, the overall results were overwhelmingly positive, with statistically significant improvements in social communication, language, restrictive/repetitive and challenging behaviours.
A small double-blind, placebo-controlled trial shows dramatic effects of suramin as a treatment for autism. Improvements were seen in all three core features of autism: language, social interactions, and restricted or repetitive behaviours across multiple diagnostics in multiple tests in all who received the active treatments, absent in the placebo arm
Numerous medical conditions are significantly more prevalent in children and adults with autism, including allergy and/or immunologic, musculoskeletal, neurologic, psychiatric and gastrointestinal conditions. Early childhood health problems can be used to spot children at high risk of autism…
Double-blind randomized multicenter trial finds bumetanide ameliorates core symptoms of autism.A medical drug normally used to relieve fluid retention has been repurposed as a treatment for the core symptoms of autism. Following on from the promising results of their...
Adrenocorticotropic hormone therapy in patients with nighttime subclinical seizure activity improves their stuttering and autism symptoms ACTH therapy improves core symptoms of autism alongside EEG parameters and sublinical seizures. In a retrospective study a total...